Octagon Capital Advisors LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Octagon Capital Advisors LP raised its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,110,167 shares of the company's stock after buying an additional 363,500 shares during the quarter. Dianthus Therapeutics comprises about 7.6% of Octagon Capital Advisors LP's investment portfolio, making the stock its 3rd biggest holding. Octagon Capital Advisors LP owned about 7.13% of Dianthus Therapeutics worth $46,002,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of DNTH. Millennium Management LLC raised its holdings in shares of Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock worth $1,972,000 after acquiring an additional 55,682 shares in the last quarter. Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock worth $23,607,000 after purchasing an additional 136,314 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Dianthus Therapeutics by 55.9% in the fourth quarter. Deutsche Bank AG now owns 20,011 shares of the company's stock worth $436,000 after acquiring an additional 7,179 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Dianthus Therapeutics by 9.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 54,766 shares of the company's stock valued at $1,194,000 after purchasing an additional 4,518 shares in the last quarter. Finally, Braidwell LP grew its position in shares of Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after acquiring an additional 712,902 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DNTH. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $20.08 on Tuesday. The company has a market capitalization of $645.09 million, a P/E ratio of -8.03 and a beta of 1.48. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27. The business's 50-day moving average price is $19.78 and its two-hundred day moving average price is $22.32.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.